

Chapter 1

Overview of Clinical Trial and Pharmacovigilance Process and Areas of Application of Computer System

Sowmyanarayan Srinivasan
Accenture Services Pvt Ltd, India

ABSTRACT

The overall process of getting a drug to the market is a long one and takes 10-15 years and costing close to a billion dollar. The success rate as the compound travels from the initial discovery phase to clinical and then through to the market is about 1 in 10,000. The two key phases which together contribute the most to the cost and timeline are clinical development and pharmacovigilance. These two phases together also account for the maximum number of failures. In this chapter, we will look in detail at these two phases with a focus on the business process and process areas which have application of computer systems. The chapter will focus on looking at the various phases of clinical development and their endpoints. Clinical development is the process of testing a drug for safety and efficacy in human subjects. Clinical trial is conducted in 3 phases with the 4th phase which is ongoing post approval which forms an important part of the pharmacovigilance process. These phases will be elaborated in detail.

INTRODUCTION AND BACKGROUND

The overall process of getting a drug to the market is a long one and takes 10-15 years and costing close to a billion dollar. The success rate as the compound travels from the initial discovery phase to clinical and then through to the market is about 1 in 10,000. The two key phases which together contribute the most to the cost and timeline are clinical development and pharmacovigilance. These two phases together also account for the maximum number of failures. In this chapter, we will look in detail at these two phases with a focus on the business process and process areas which have application of computer systems.

DOI: 10.4018/978-1-5225-1762-7.ch001

Figure 1 illustrates the value chain of bringing a drug to the market starting from understanding of disease to commercialization of the drug for the disease. (R&D Pipeline Management, University of Wisconsin, n.d)

The entire process of drug discovery and development starts *in silico* (in the computer), moves to *in vitro* (in the laboratories) and then finally *in vivo* (inside living beings like animals and humans). This is keeping with the spirit of ensuring safety to all living beings. As the molecule progresses to becoming a drug it graduates from computer to laboratory to living beings.

The initial phase of drug discovery is focused on understanding the disease better and potential drug targets that are relevant for the disease which is largely driven by biology. This part primarily focuses on:

- Understanding the mechanism of diseases;
- Identifying potential targets for therapeutic intervention;
- Evaluating potential drug candidates.

Once the disease is better understood and potential targets identified, the next phase focuses on various aspects of the molecule that can become potential drugs and is largely driven by chemistry. This part addresses the following needs:

- Inventing or identifying safe & effective chemical entities that will become potential drug candidates.
- These drug candidates will act as leads to act on the target disease


These two initial phases of biology and chemistry are largely *in silico* and *in vitro*.

One of the key qualifying parameter for a molecule to become a drug is its medicinal properties. This science is called medicinal chemistry and this characterizes the molecule before it is used in any living being.

Medicinal chemistry is a scientific discipline involved with designing, synthesizing and developing pharmaceutical drugs.

Medicinal chemistry involves the identification, synthesis and development of new chemical entities suitable for therapeutic use. It also includes the study of existing drugs, their biological properties, and

Figure 1.



11 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:
www.igi-global.com/chapter/overview-of-clinical-trial-and-pharmacovigilance-process-and-areas-of-application-of-computer-system/174118

Related Content

The "ETA" Indices in QSAR/QSPR/QSTR Research

Kunal Roy and Rudra Narayan Das (2015). *Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment* (pp. 48-83).

www.irma-international.org/chapter/the-eta-indices-in-qsarqsprqstr-research/124467

Moving into Nanotechnology Roles to Mimic and Boost Enzyme Activity

Maria Laura Soriano (2018). *Research Advancements in Pharmaceutical, Nutritional, and Industrial Enzymology* (pp. 421-440).

www.irma-international.org/chapter/moving-into-nanotechnology-roles-to-mimic-and-boost-enzyme-activity/203826

Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer

Tarun Jha, Nilanaj Adhikari, Amit Kumar Halder and Achintya Saha (2015). *Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment* (pp. 400-470).

www.irma-international.org/chapter/ligand--and-structure-based-drug-design-of-non-steroidal-aromatase-inhibitors-nsais-in-breast-cancer/124476

Open Access Initiatives in Medical Biology: A Study of Institutional Repositories in India

Rupak Chakravarty (2016). *Advancing Pharmaceutical Processes and Tools for Improved Health Outcomes* (pp. 24-51).

www.irma-international.org/chapter/open-access-initiatives-in-medical-biology/150014

A Field Study for Milk Safety and Quality Determination of Heavy Metal Concentration in Raw Milk: Dairy Science and Technology

Bardhyl Limani, Mohammad Ayaz Ahmad, Vesna Karapetkovska Hristova, Antalov Jagnandan, Syed Khalid Mustafa, Jalal Hasan Baker, Samira Jebahi, Mohammad Rehan Ajmal and Abdul Mosawir Quraishi (2023). *Cases on Teaching Pharmacology to Complementary and Alternative Medicine Students* (pp. 150-182).

www.irma-international.org/chapter/a-field-study-for-milk-safety-and-quality-determination-of-heavy-metal-concentration-in-raw-milk/320638